Ergomed (ERGO) Share Price, News & Analysis

Company Overview

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Key Stats

• Today's Range: 1,346 to 1,346
• 50-Day Range: 1,346 to 1,346
• 52-Week Range: 895 to 1,380
• Volume: 280,999 shs
• Average Volume: 346,578 shs
• Market Capitalization: £701.00 million
• P/E Ratio: 4,641.38
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ERGO Stock Analysis - Frequently Asked Questions

How have ERGO shares performed this year?

Ergomed's stock was trading at GBX 1,346 at the start of the year. Since then, ERGO stock has increased by 0.0% and is now trading at GBX 1,346.
View the best growth stocks for 2024 here.

How were Ergomed's earnings last quarter?

Ergomed plc (LON:ERGO) announced its quarterly earnings results on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The business had revenue of $22.91 million for the quarter. Ergomed had a trailing twelve-month return on equity of 18.08% and a net margin of 9.87%.

How do I buy shares of Ergomed?

Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Ergomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), FuelCell Energy (FCEL), Frontier Developments (FDEV), Future (FUTR), Lloyds Banking Group (LLOY) and NIO (NIO).

Company Calendar

• Last Earnings: 9/18/2017
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:ERGO
• CUSIP: N/A
• CIK: N/A
• Web: www.ergomedplc.com
• Phone: +44-1483-503205
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.29
• Trailing P/E Ratio: 4,641.38
• Forward P/E Ratio: 26.11
• P/E Growth: N/A
• Net Income: £15 million
• Net Margins: 9.87%
• Pretax Margin: N/A
• Return on Equity: 18.08%
• Return on Assets: 10.16%

Debt

• Debt-to-Equity Ratio: 3.32
• Current Ratio: 1.79
• Quick Ratio: 1.22

Sales & Book Value

• Annual Sales: £152.09 million
• Price / Sales: 4.61
• Cash Flow: GBX 24.62 per share
• Price / Cash Flow: 54.67
• Book Value: GBX 179 per share
• Price / Book: 7.52

Miscellaneous

• Outstanding Shares: 52,080,000
• Free Float: N/A
• Market Cap: £701.00 million
• Optionable: Not Optionable
• Beta: 0.79